EXHIBIT C TO PETITION

Amendments To The Claims

--1. (Currently Amended) A composition adapted for intra-articular administration for the treatment and/or prevention of damaged articular cartilage of a diarthrodial joint in man or in animals, the composition comprising therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

2. (Original) The composition of claim 1, wherein the therapeutic amount of chondroitin sulfate comprises from between about 0.5 grams to about 1.5 grams of a suitable chondroitin sulfate per unit dose of the composition.

3. (Original) The composition of claim 2, wherein the suitable chondroitin sulfate is CS4 chondroitin sulfate.

4. (Original) The composition of claim 2, wherein the suitable chondroitin sulfate is CS6 chondroitin sulfate.

5. (Original) The composition of claim 2, wherein the suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.

6. (Original) The composition of claim 1, wherein the therapeutic amount of N acetyl D-glucosamine is from about 0.5 grams to about 1.5 grams of N acetyl D-glucosamine per unit dose of the composition.

7. (Original) The composition of claim 1, wherein the therapeutic amount of hyaluronan is from about 10 mg to about 50 mg of hyaluronan per unit dose of the composition.

8. (Original) The composition of claim 1 as a sterile solution.

9. (Original) The composition of claim 1 as a sterile suspension.

10. (Currently Amended) A composition adapted for parenteral administration for the treatment and/or prevention of damaged articular cartilage of a diarthrodial joint in man or in animals, the composition consisting essentially of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

11. (Original) A composition adapted for the treatment and/or prevention of traumatic synovitis in man or in animals, the composition comprising therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

12. (Original) The composition in claim 11 is wherein the therapeutic amount of chondroitin sulfate comprises from between about 0.5 grams to about 1.5 grams of a suitable chondroitin sulfate per unit dose of the composition.

13. (Original) The composition of claim 12, wherein the suitable chondroitin sulfate is CS4 chondroitin sulfate.

14. (Original) The composition of claim 12, wherein the suitable chondroitin sulfate is CS6 chondroitin sulfate.

15. (Original) The composition of claim 12, wherein the suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.

16. (Original) The composition of claim 1 1, wherein the therapeutic amount of N acetyl D-glucosamine is from about 0.5 grams to about 1.5 grams of N acetyl D-glucosamine

per unit dose of the composition.

17. (Original) The composition of claim 11, wherein the therapeutic amount of hyaluronan is from about 10 mg to about 50 mg of hyaluronan per unit dose of the composition.

18. (Original) The composition of claim 11 as a sterile solution.

19. (Original) The composition of claim 11 as a sterile suspension.

20. (Original) A composition adapted for the treatment and/or prevention of traumatic synovitis in man or in animals, the composition consisting essentially of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

21. (Original) A method for the treatment and/or prevention of damaged articular cartilage of a diarthrodial joint in man or in animals, comprising administering a therapeutic amount of a composition comprised of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

22. (Original) The method in claim 21, wherein the therapeutic composition is administered intra-articular.

23. (Original) The method in claim 21, wherein the therapeutic composition is administered intramuscularly.

24. (Original) The method in claim 21, wherein the therapeutic composition is administered intravenously.

25. (Original) A method for the treatment and/or prevention of damaged articular

cartilage of a diarthrodial joint in man or in animals, comprising administering a therapeutic amount of a composition consisting essentially of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

26. (Original) The method in claim 25, wherein the therapeutic composition is administered intra-articular.

27. (Original) The method in claim 25, wherein the therapeutic composition is administered intramuscularly.

28. (Original) The method in claim 25, wherein the therapeutic composition is administered intravenously.

29. (Original) A method for the treatment and/or prevention of a damaged synovial membrane, traumatic synovitis, in man or in animals, comprising administering a therapeutic amount of a composition comprised of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

30. (Original) The method in claim 29, wherein the therapeutic composition is administered intra-articular.

31. (Original) The method in claim 29, wherein the therapeutic composition is administered intramuscularly.

32. (Original) The method in claim 29, wherein the therapeutic composition is administered intravenously.

33. (Original) A method for the treatment and/or prevention of damaged synovial

membrane, traumatic synovitis, in man or in animals, comprising administering a therapeutic amount of a composition consisting essentially of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

34. (Original) The method in claim 33, wherein the therapeutic composition is administered intra-articular.

35. (Original) The method in claim 33, wherein the therapeutic composition is administered intramuscularly.

36. (Original) The method in claim 33, wherein the therapeutic composition is administered intravenously.--